OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 1.

Table. 1.

Ongoing clinical trials using liquid biopsy for somatic mutation detection in gastric cancer

Study No. Study type Status Start date Conditions Primary outcome measure
NCT06036563 O N/R Sep 2023 Common cancers Diagnostic accuracy of cfDNA for screening and differentiating common cancers, including gastric cancer, in participants compared with a reference histological test
NCT06028724 O R May 2023 Solid tumors Prevalence of clinically useful mutations in solid tumors, including gastric cancer by a next-generation sequencing-based cfDNA method
NCT05366881 O R May 2022 Multiple types of cancer Differentiation between cancer and non-cancer signals from patients and controls based on cfDNA analysis using a genome-wide methylome enrichment platform
NCT05227261 O R Apr 2022 Common cancers of the lung, breast, liver, colorectum, and stomach Positive/negative predictive values of blood cfDNA in early cancer detection
NCT05347524 O R Mar 2022 Gastric cancer with peritoneal metastasis Sensitivity and specificity of cfDNA methylation-based assay for detecting peritoneal metastasis of gastric cancer
NCT05513144 O R Dec 2021 Advanced ERBB2-negative gastric cancer Molecular changes over the course of disease progression may serve as a prognostic marker for diagnosis and treatment response
NCT05027347 O R Oct 2021 Early-stage gastric cancer Sensitivity and specificity of a cfDNA assay for detecting early-stage gastric cancer
NCT05029869 O R Oct 2021 Gastric cancer after gastrectomy Sensitivity of a cfDNA assay for monitoring minimal residual disease
NCT05059444 O R Sep 2021 Early-stage solid tumors treated Detection of distant recurrence-free intervals in individuals treated for early-stage solid tumors
NCT05224596 O R Jan 2021 Gastric cancer Sensitivity and specificity of a cfDNA methylation-based assay for detecting gastric cancer
NCT04253106 I R Nov 2020 Hereditary diffuse gastric cancer Percentage of patients with somatic mutations or methylation profiles using liquid biopsy
NCT04484636 I R Oct 2020 Gastrointestinal cancer Measurement of genomic profiles
NCT04943406 O R May 2020 Locally advanced gastric cancer Overall and disease-free survival based on ctDNA positivity in peritoneal lavage and peripheral blood of patients with locally advanced gastric cancer
NCT03957564 I R May 2019 Gastric cancer, gastro-esophageal junction cancer Detection of circulating tumor cells and cfDNA before and after neoadjuvant chemotherapy and surgery

The information of clinical trials was obtained from http://clinicaltrials.gov (accessed on October 2, 2023).

Abbreviations: O, observational; I, interventional; R, recruiting; N/R, not yet recruiting; cfDNA, cell-free DNA.

Ann Lab Med 2024;44:119~121 https://doi.org/10.3343/alm.2023.0391

© Ann Lab Med